<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548485" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548485/" /><meta name="ncbi_pagename" content="Rasburicase - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Rasburicase - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Rasburicase" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2018/05/21" /><meta name="citation_pmid" content="31643804" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548485/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Rasburicase" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2018/05/21" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548485/" /><meta name="description" content="Rasburicase is a parenterally administered, recombinant urate oxidase that is used in combination with xanthine oxidase inhibitors in the therapy of severe hyperuricemia due to tumor lysis syndrome after initiation of cancer chemotherapy in treatment of malignant diseases. Rasburicase has been associated with serum enzyme elevations during therapy and to rare instances of hypersensitivity reactions that can be accompanied by liver injury." /><meta name="og:title" content="Rasburicase" /><meta name="og:type" content="book" /><meta name="og:description" content="Rasburicase is a parenterally administered, recombinant urate oxidase that is used in combination with xanthine oxidase inhibitors in the therapy of severe hyperuricemia due to tumor lysis syndrome after initiation of cancer chemotherapy in treatment of malignant diseases. Rasburicase has been associated with serum enzyme elevations during therapy and to rare instances of hypersensitivity reactions that can be accompanied by liver injury." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548485/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Rasburicase/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548485/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8D13C204688C310000000001FC0092.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548485_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548485_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Rasagiline/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Ravulizumab/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548485_"><span class="title" itemprop="name">Rasburicase</span></h1><p class="small">Last Update: <span itemprop="dateModified">May 21, 2018</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Rasburicase.OVERVIEW"><h2 id="_Rasburicase_OVERVIEW_">OVERVIEW</h2><div id="Rasburicase.Introduction"><h3>Introduction</h3><p>Rasburicase is a parenterally administered, recombinant urate oxidase that is used in combination with xanthine oxidase inhibitors in the therapy of severe hyperuricemia due to tumor lysis syndrome after initiation of cancer chemotherapy in treatment of malignant diseases. Rasburicase has been associated with serum enzyme elevations during therapy and to rare instances of hypersensitivity reactions that can be accompanied by liver injury.</p></div><div id="Rasburicase.Background"><h3>Background</h3><p>Rasburicase (ras bure&#x02019; i kase) is a DNA recombinant urate oxidase derived from the fungus Aspergillus flavus. Urate oxidase is an enzyme that catalyzes the metabolism of uric acid to allantoin, which is an inert and inactive molecule that, unlike uric acid, is rapidly excreted in the urine. Infusions of rasburicase lower serum uric acid levels by hastening its excretion and have been shown to be effective in rapidly lowering uric acid levels in patients with tumor lysis syndrome after initiation of cancer chemotherapy. Rasburicase was approved for use in the treatment and prevention of hyperuricemia due to tumor lysis syndrome after cancer chemotherapy in the United States in 2002. Rasburicase is available as a powder for reconstitution in vials of 1.5 and 7.5 mg under the brand name Elitek. The recommended dose is 0.2 mg/kg given intravenously once daily for up to 5 days. Common side effects of rasburicase include nausea, vomiting, fever, peripheral edema, anxiety, headache, abdominal pain, constipation and diarrhea. Severe adverse reactions can include local infusion reactions, hypersensitivity reactions, anaphylaxis and hemolytic anemia with methemoglobinemia in patients with G6PD deficiency.</p></div><div id="Rasburicase.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>In prelicensure clinical trials, serum enzyme elevations were not uncommon (4% to 24%) and were occasionally above 5 times ULN (&#x0003c;1%) during rasburicase therapy. These elevations generally resolved rapidly once rasburicase was discontinued. Because patients receiving rasburicase were typically receiving cancer chemotherapy and other drugs for hyperuricemia such as allopurinol, the liver enzyme elevations observed could not always be attributed to rasburicase. Subsequent to its approval and more wide scale use, rasburicase has been linked to hypersensivity reactions that may be accompanied by marked serum <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> and <a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a> elevations with mild jaundice. In at least one instance, these abnormalities recurred upon re-exposure to rasburicase. These reactions generally arise within hours of administration of rasburicase and resolve rapidly with its discontinuation with or without the use of corticosteroids. Rasburicase has not been linked to instances of acute liver failure or chronic liver injury. Thus, rasburicase is a well-known cause of hypersensivity reactions, some of which may be accompanied by hepatic injury.</p><p>Likelihood score: D (possible cause of clinically apparent liver injury accompanying hypersensitivity reactions).</p></div><div id="Rasburicase.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>Rasburicase is a recombinant protein and is metabolized to amino acids by serum and tissue proteases, and is unlikely to have any direct hepatotoxic potential. The marked liver test abnormalities noted in some patients treated with rasburicase were associated with other features of hypersensitivity.</p></div><div id="Rasburicase.Outcome_and_Management"><h3>Outcome and Management</h3><p>The serum enzyme elevations during rasburicase therapy are usually mild-to-moderate in severity and rarely require dose modification. Hypersensitivity reactions to rasburicase can be accompanied by mild-to-moderate liver injury. Therapy should be directed at the signs and symptoms of hypersensitivity rather than liver injury itself.</p><p>Drug Class: <a href="/books/n/livertox/AntiGoutAgents/">Antigout Agents</a></p></div></div><div id="Rasburicase.CASE_REPORT"><h2 id="_Rasburicase_CASE_REPORT_">CASE REPORT</h2><div id="Rasburicase.Case_1._Hypersensitivity_rea"><h3>Case 1. Hypersensitivity reaction with hepatic involvement caused by rasburicase.</h3><p>[Modified from: Viel S, Pescarmona R, Belot A, Nosbaum A, Lombard C, Walzer T, B&#x000e9;rard F. A case of type 2 hypersensitivity to rasburicase diagnosed with a natural killer cell activation assay. Front Immunol 2018; 9: 110. <a href="https://www.ncbi.nlm.nih.gov/pubmed/29434608" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed Citation</a>]</p><p>A 62 year old man with leukemia developed fever and liver test abnormalities during his fourth course of chemotherapy with pentostatin and tumor lysis syndrome prophylaxis using allopurinol and rasburicase. His white blood cell counts were elevated and he was admitted for therapy of suspected sepsis. His medications were stopped. He had no previous history of liver disease, alcohol abuse or risk factors for viral hepatitis. Laboratory testing showed marked elevations in serum aminotransferase levels (<a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> 1102 U/L, <a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a> 773 U/L and LDH 1339 U/L with mild hyperbilirubinemia (3.3 mg/dL) and decrease in the prothrombin index (46%) (Table). His condition improved rapidly and he was discharged. Two months later he was evaluated for hypersensitivity to rasburicase with skin tests. An hour after the single dose of rasburicase (5.5 mg), he developed fever (39.5 <sup>o</sup>C) and liver tests were again raised.</p><div id="Rasburicase.Key_Points"><h4>Key Points</h4><div id="Rasburicase.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548485/table/Rasburicase.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Rasburicase.T1_lrgtbl__"><table><tbody><tr><th id="hd_b_Rasburicase.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Medication:</th><td headers="hd_b_Rasburicase.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Rasburicase</td></tr><tr><th id="hd_b_Rasburicase.T1_1_1_2_1" rowspan="1" colspan="1" style="vertical-align:top;">Pattern:</th><td headers="hd_b_Rasburicase.T1_1_1_2_1" rowspan="1" colspan="1" style="vertical-align:top;">Hepatocellular</td></tr><tr><th id="hd_b_Rasburicase.T1_1_1_3_1" rowspan="1" colspan="1" style="vertical-align:top;">Severity:</th><td headers="hd_b_Rasburicase.T1_1_1_3_1" rowspan="1" colspan="1" style="vertical-align:top;">3+ (jaundice, hospitalization)</td></tr><tr><th id="hd_b_Rasburicase.T1_1_1_4_1" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Rasburicase.T1_1_1_4_1" rowspan="1" colspan="1" style="vertical-align:top;">4 months</td></tr><tr><th id="hd_b_Rasburicase.T1_1_1_5_1" rowspan="1" colspan="1" style="vertical-align:top;">Recovery:</th><td headers="hd_b_Rasburicase.T1_1_1_5_1" rowspan="1" colspan="1" style="vertical-align:top;">Within 2 months</td></tr><tr><th id="hd_b_Rasburicase.T1_1_1_6_1" rowspan="1" colspan="1" style="vertical-align:top;">Other medications:</th><td headers="hd_b_Rasburicase.T1_1_1_6_1" rowspan="1" colspan="1" style="vertical-align:top;">Allopurinol, pentostatin</td></tr></tbody></table></div></div></div><div id="Rasburicase.Laboratory_Values"><h4>Laboratory Values</h4><div id="Rasburicase.T2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548485/table/Rasburicase.T2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Rasburicase.T2_lrgtbl__"><table><tbody><tr><th id="hd_b_Rasburicase.T2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After Starting</th><th id="hd_b_Rasburicase.T2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After Stopping</th><th id="hd_b_Rasburicase.T2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> (U/L)</th><th id="hd_b_Rasburicase.T2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.gamma-glutamyl-transpeptidase-ggt-/">GGT</a> (U/L)</th><th id="hd_b_Rasburicase.T2_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a> (mg/dL)</th><th id="hd_b_Rasburicase.T2_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Other</th></tr><tr><td headers="hd_b_Rasburicase.T2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">4 months</td><td headers="hd_b_Rasburicase.T2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">0</td><td headers="hd_b_Rasburicase.T2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">1102</td><td headers="hd_b_Rasburicase.T2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">307</td><td headers="hd_b_Rasburicase.T2_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">3.3</td><td headers="hd_b_Rasburicase.T2_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Fever and leukocytosis</td></tr><tr><td headers="hd_b_Rasburicase.T2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"></td><td headers="hd_b_Rasburicase.T2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">2 days</td><td headers="hd_b_Rasburicase.T2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">863</td><td headers="hd_b_Rasburicase.T2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">225</td><td headers="hd_b_Rasburicase.T2_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">5.9</td><td headers="hd_b_Rasburicase.T2_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Prothrombin ratio [PR] 46%</td></tr><tr><td headers="hd_b_Rasburicase.T2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"></td><td headers="hd_b_Rasburicase.T2_1_1_1_2 hd_b_Rasburicase.T2_1_1_1_3 hd_b_Rasburicase.T2_1_1_1_4 hd_b_Rasburicase.T2_1_1_1_5" colspan="4" rowspan="1" style="text-align:center;vertical-align:middle;">Discharged, chemotherapy withheld</td><td headers="hd_b_Rasburicase.T2_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"></td></tr><tr><td headers="hd_b_Rasburicase.T2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">6 months</td><td headers="hd_b_Rasburicase.T2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">2 months</td><td headers="hd_b_Rasburicase.T2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">43</td><td headers="hd_b_Rasburicase.T2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">22</td><td headers="hd_b_Rasburicase.T2_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">0.4</td><td headers="hd_b_Rasburicase.T2_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">PR 98%</td></tr><tr><td headers="hd_b_Rasburicase.T2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"></td><td headers="hd_b_Rasburicase.T2_1_1_1_2 hd_b_Rasburicase.T2_1_1_1_3 hd_b_Rasburicase.T2_1_1_1_4 hd_b_Rasburicase.T2_1_1_1_5" colspan="4" rowspan="1" style="text-align:center;vertical-align:middle;">Skin tested with rasburicase</td><td headers="hd_b_Rasburicase.T2_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"></td></tr><tr><td headers="hd_b_Rasburicase.T2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"></td><td headers="hd_b_Rasburicase.T2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">3 hours</td><td headers="hd_b_Rasburicase.T2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">73</td><td headers="hd_b_Rasburicase.T2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">99</td><td headers="hd_b_Rasburicase.T2_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">1.0</td><td headers="hd_b_Rasburicase.T2_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">PR 90%</td></tr><tr><td headers="hd_b_Rasburicase.T2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"></td><td headers="hd_b_Rasburicase.T2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">6 hours</td><td headers="hd_b_Rasburicase.T2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">257</td><td headers="hd_b_Rasburicase.T2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">202</td><td headers="hd_b_Rasburicase.T2_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">1.5</td><td headers="hd_b_Rasburicase.T2_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">PR 77%</td></tr><tr><td headers="hd_b_Rasburicase.T2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"></td><td headers="hd_b_Rasburicase.T2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">24 hours</td><td headers="hd_b_Rasburicase.T2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">220</td><td headers="hd_b_Rasburicase.T2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">171</td><td headers="hd_b_Rasburicase.T2_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"></td><td headers="hd_b_Rasburicase.T2_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">PR 54%</td></tr><tr><td headers="hd_b_Rasburicase.T2_1_1_1_1 hd_b_Rasburicase.T2_1_1_1_2" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;"><b>Normal Values</b></td><td headers="hd_b_Rasburicase.T2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><b>&#x0003c;55</b></td><td headers="hd_b_Rasburicase.T2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><b>&#x0003c;64</b></td><td headers="hd_b_Rasburicase.T2_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><b>&#x0003c;1.2</b></td><td headers="hd_b_Rasburicase.T2_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"></td></tr></tbody></table></div></div></div><div id="Rasburicase.Comment"><h4>Comment</h4><p>This patient presented with a hypersensitivity reaction with hepatic involvement resulting in mild jaundice, but a self-limited course. He was later evaluated with skin testing for drug allergy in an attempt to show whether the reaction was due to rasburicase versus allopurinol or pentostatin. After a single intradermal injection of rasburicase, he developed fever followed by elevations in serum aminotransferase levels and total bilirubin. Thus, the role of rasburicase in the reaction was fairly convincingly documented.</p></div></div></div><div id="Rasburicase.PRODUCT_INFORMATION"><h2 id="_Rasburicase_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><div id="Rasburicase.BPI" class="box"><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Rasburicase &#x02013; Elitek&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antigout Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Rasburicase" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></div><div id="Rasburicase.CHEMICAL_FORMULA_AND_STRUCTU"><h2 id="_Rasburicase_CHEMICAL_FORMULA_AND_STRUCTU_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Rasburicase.T3" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548485/table/Rasburicase.T3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Rasburicase.T3_lrgtbl__"><table><thead><tr><th id="hd_h_Rasburicase.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">DRUG</th><th id="hd_h_Rasburicase.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">CAS REGISTRY NO</th><th id="hd_h_Rasburicase.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Rasburicase.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Rasburicase.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Rasburicase</td><td headers="hd_h_Rasburicase.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135272107" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">134774-45-1</a></td><td headers="hd_h_Rasburicase.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</td><td headers="hd_h_Rasburicase.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Complex Polypeptide</td></tr></tbody></table></div></div></div><div id="Rasburicase.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Rasburicase_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 21 May 2018</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Rasburicase.R1">Zimmerman HJ. Drugs used to treat gout. Drugs used to treat rheumatic and musculospastic disease. In, Zimmerman, HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999: pp. 543-4.<div><i>(Textbook of hepatotoxicity published in 1999 and before the availability of rasburicase).</i></div></div></li><li><div class="bk_ref" id="Rasburicase.R2">Grosser T, Smyth E, FitzGerald GA. Pharmacotherapy of gout. Anti-inflammatory, antipyretic and analgesic agents; pharmacotherapy of gout. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 994-1000.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Rasburicase.R3">Pui CH, Jeha S, Irwin D, Camitta B. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 2001; 15: 1505-9.  [<a href="/pubmed/11587206" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11587206</span></a>]<div><i>(Among 173 children and 72 adults receiving cancer chemotherapy who were treated with rasburicase, all had a rapid decline in serum uric acid, usually into the normal range and side effects included vomiting, itching, urticarial, rash, fever, headache and myalgia).</i></div></div></li><li><div class="bk_ref" id="Rasburicase.R4">Rasburicase (Elitek) for hyperuricemia. Med Lett Drugs Ther 2002; 44 (1143): 96-7.  [<a href="/pubmed/12432325" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12432325</span></a>]<div><i>(Concise review of the indications, pharmacology, clinical efficacy, side effects and costs of rasburicase shortly after its approval for use in the US mentions anaphylactic reactions, but not ALT elevations or liver injury).</i></div></div></li><li><div class="bk_ref" id="Rasburicase.R5">Coiffier B, Mounier N, Bologna S, Ferm&#x000e9; C, Tilly H, Sonet A, Christian B, et al.; Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 study. J Clin Oncol 2003; 21: 4402-6.  [<a href="/pubmed/14581437" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14581437</span></a>]<div><i>(Among 100 patients with lymphoma undergoing chemotherapy who received rasburicase infusions, uric acid levels were controlled in all patients and none required dialysis during chemotherapy; therapy was stopped early in 3 patients for ALT elevations above 5 times ULN, which rapidly resolved).</i></div></div></li><li><div class="bk_ref" id="Rasburicase.R6">Jeha S, Kantarjian H, Irwin D, Shen V, Shenoy S, Blaney S, Camitta B, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 2005; 19: 34-8.  [<a href="/pubmed/15510203" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15510203</span></a>]<div><i>(Among 658 children and 338 adults with malignancies who received rasburicase at the time of chemotherapy, uric acid levels fell and the only nonresponders had discontinued therapy early; side effects were rare but included hemolytic anemia due to G6PD deficiency, renal insufficiency, hypersensitivity reactions, but only one patient had ALT elevations above 5 times ULN).</i></div></div></li><li><div class="bk_ref" id="Rasburicase.R7">Kikuchi A, Kigasawa H, Tsurusawa M, Kawa K, Kikuta A, Tsuchida M, Nagatoshi Y, et al. A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome. Int J Hematol 2009; 90: 492-500.  [<a href="/pubmed/19701676" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19701676</span></a>]<div><i>(Among 30 children with hematologic malignancies given rasburicase for 5 days during initial chemotherapy, serum uric acid levels remained below 6.5 mg/dL in all except one patient; ALT elevations above 5 times ULN occurred in 70% of children, but were attributed to the chemotherapy rather than rasburicase).</i></div></div></li><li><div class="bk_ref" id="Rasburicase.R8">Ishizawa K, Ogura M, Hamaguchi M, Hotta T, Ohnishi K, Sasaki T, Sakamaki H, et al. Safety and efficacy of rasburicase (SR29142) in a Japanese phase II study. Cancer Sci. 2009; 100 (2): 357-62.  [<a href="/pubmed/19076979" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19076979</span></a>]<div><i>(Among 50 patients with lymphoma or leukemia treated with rasburicase for 5 days starting after the first dose of chemotherapy, serum uric acid levels fell and were less than 7.5 mg/dL in all, while side effects included ALT elevations in 24% [above 5 times ULN in 4%], which resolved after therapy in all and hypersensitivity reactions in 3 patients [6%]).</i></div></div></li><li><div class="bk_ref" id="Rasburicase.R9">Cortes J, Moore JO, Maziarz RT, Wetzler M, Craig M, Matous J, Luger S, et al. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. J Clin Oncol 2010; 28: 4207-13.  [<a href="/pmc/articles/PMC4979236/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4979236</span></a>] [<a href="/pubmed/20713865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20713865</span></a>]<div><i>(Among 273 children with hematologic malignancies treated with rasburicase, allopurinol or both for 5 days at the start of chemotherapy, uric acid responses were more frequent and rapid with rasburicase, and hypersensitivity reactions arose in 4% and liver test abnormalities in 1% of rasburicase recipients).</i></div></div></li><li><div class="bk_ref" id="Rasburicase.R10">Galardy PJ, Hochberg J, Perkins SL, Harrison L, Goldman S, Cairo MS. Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report. Br J Haematol 2013; 163: 365-72.  [<a href="/pmc/articles/PMC3835461/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3835461</span></a>] [<a href="/pubmed/24032600" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24032600</span></a>]<div><i>(Among 76 children undergoing cytoreductive therapy in preparation of hematopoietic cell transplantation who received rasburicase to prevent tumor lysis syndrome, 3 patients developed hypersensitivity symptoms, but there were no serious adverse events attributed to the rasburicase therapy).</i></div></div></li><li><div class="bk_ref" id="Rasburicase.R11">Digumarti R, Sinha S, Nirni SS, Patil SG, Pedapenki RM. Efficacy of rasburicase (recombinant urate oxidase) in the prevention and treatment of malignancy-associated hyperuricemia: an Indian experience. Indian J Cancer 2014; 51: 180-3.  [<a href="/pubmed/25104205" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25104205</span></a>]<div><i>(Among 88 patients at high risk of tumor lysis syndrome from chemotherapy who received rasburicase, uric acid levels decreased by an average of 75% and there were &#x0201c;no significant changes in &#x02026; biochemical parameters from baseline&#x0201d; and no serious adverse events thought to be related to rasburicase).</i></div></div></li><li><div class="bk_ref" id="Rasburicase.R12">Drugs for gout. Med Lett Drugs Ther 2014; 56 (1438): 22-4.  [<a href="/pubmed/24791281" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24791281</span></a>]<div><i>(Update on medications for gout discusses the urate lowering agents allopurinol, febuxostat, probenecid and pegloticase, but not lesinurad or rasburicase).</i></div></div></li><li><div class="bk_ref" id="Rasburicase.R13">Baldo BA. Enzymes approved for human therapy: indications, mechanisms and adverse effects. BioDrugs 2015; 29: 31-55.  [<a href="/pubmed/25648140" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25648140</span></a>]<div><i>(Review of enzymes that are approved for use in the US including those used for enzyme replacement therapy [for Gaucher, Fabry, Pompe, and several MPS] as well as those for specific diseases [dornase for cystic fibrosis, alteplase for myocardial infarction and stoke, L-asparaginase for cancer and pegloticase and rasburicase for hyperuricemia and gout]; no mention of ALT elevations or hepatotoxicity except for L-asparaginase).</i></div></div></li><li><div class="bk_ref" id="Rasburicase.R14">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52.  [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury in the US collected between 2004 and 2012, 8 cases were attributed to drugs used for gout [allopurinol in 7 and febuxostat in 1], but no cases were attributed to pegloticase or rasburicase).</i></div></div></li><li><div class="bk_ref" id="Rasburicase.R15">Tamura K, Kawai Y, Kiguchi T, Okamoto M, Kaneko M, Maemondo M, Gemba K, et al. Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. Int J Clin Oncol 2016; 21 (5): 996-1003.  [<a href="/pubmed/27017611" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27017611</span></a>]<div><i>(Among 100 patients with malignancies undergoing chemotherapy who were treated prophylactically with either allopurinol or febuxostat, the rate and degree of uric acid decline and side effects were similar in the two groups, and 1 patient in each group had serum ALT elevations [both were less than 3 times ULN]). </i></div></div></li><li><div class="bk_ref" id="Rasburicase.R16">Viel S, Pescarmona R, Belot A, Nosbaum A, Lombard C, Walzer T, B&#x000e9;rard F. A case of type 2 hypersensitivity to rasburicase diagnosed with a natural killer cell activation assay. Front Immunol 2018; 9: 110.  [<a href="/pmc/articles/PMC5796899/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5796899</span></a>] [<a href="/pubmed/29434608" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29434608</span></a>]<div><i>(62 year old man developed fever and jaundice during a 4th course of chemotherapy while receiving allopurinol and rasburicase [bilirubin 3.3 mg/dL, ALT 1162 U/L, GGT 307 U/L, leukocytosis], which rapidly resolved on stopping but recurred several months later after a skin test challenge with rasburicase [bilirubin 1.5 mg/dL, ALT 257 U/L, GGT 202 U/L], resolving rapidly).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548485</span><span class="label">PMID: <a href="/pubmed/31643804" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643804</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Rasagiline/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Ravulizumab/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548485&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548485/?report=reader">PubReader</a></li><li><a href="/books/NBK548485/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548485" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548485" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Rasburicase. [Updated 2018 May 21].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548485/pdf/Bookshelf_NBK548485.pdf">PDF version of this page</a> (104K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=Rasburicase/AE+AND+Human%5BMH%5D+AND+(drug-induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI+OR+hepatitis,+toxic%5BMH%5D)+AND+(%222010/1/1%22%5BEDat%5D%3A%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Rasburicase: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Rasburicase" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Rasburicase: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4854962" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4854962" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4854962" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/15571272" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Management of hyperuricemia with rasburicase review.</a><span class="source">[Nucleosides Nucleotides Nuclei...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Management of hyperuricemia with rasburicase review.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">de Bont JM, Pieters R. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Nucleosides Nucleotides Nucleic Acids. 2004 Oct; 23(8-9):1431-40. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/12942574" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.</a><span class="source">[Cancer. 2003]</span><div class="brieflinkpop offscreen_noflow">Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bosly A, Sonet A, Pinkerton CR, McCowage G, Bron D, Sanz MA, Van den Berg H. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Cancer. 2003 Sep 1; 98(5):1048-54. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/12521386" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Prevention and treatment of hyperuricemia in hematological malignancies.</a><span class="source">[Clin Lymphoma. 2002]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Prevention and treatment of hyperuricemia in hematological malignancies.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Cairo MS. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Clin Lymphoma. 2002 Dec; 3 Suppl 1:S26-31. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/14581437" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.</a><span class="source">[J Clin Oncol. 2003]</span><div class="brieflinkpop offscreen_noflow">Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Coiffier B, Mounier N, Bologna S, Ferm C, Tilly H, Sonet A, Christian B, Casasnovas O, Jourdan E, Belhadj K, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Clin Oncol. 2003 Dec 1; 21(23):4402-6. Epub 2003 Oct 27.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31088218" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">A retrospective analysis of tumor lysis syndrome management in a quaternary care hospital.</a><span class="source">[J Oncol Pharm Pract. 2020]</span><div class="brieflinkpop offscreen_noflow">A retrospective analysis of tumor lysis syndrome management in a quaternary care hospital.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Eng S, Lee CS, Ahn S, Sharma A. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Oncol Pharm Pract. 2020 Mar; 26(2):338-344. Epub 2019 May 14.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643804" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643804" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class="&#10;                        HTOn&#10;                    "><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T16:04:07-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal106&amp;ncbi_phid=CE8D13C204688C310000000001FC0092&amp;ncbi_session=CE8D13C204691451_0508SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548485%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548485&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548485/&amp;ncbi_pagename=Rasburicase - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8D13C204691451_0508SID /projects/books/PBooks@9.2 portal106 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>